SCHEMBL6561273

SCHEMBL6561273

COC(=O)[C@@H](N)Cc1ccc(OCc2c(Cl)cccc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ITGA4 P13612 16/20 0.55
ITGB1 P05556 4/20 0.55
LTA4H P09960 2/20 0.52
PPARG P37231 1/20 0.45
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5719575 1.00 ITGA4 (0.55) ITGA4ITGB1LTA4HPPARGPTGS2
Hydrochloric Acid SCHEMBL6509920 0.99 ITGA4 (0.54) ITGA4ITGB1LTA4HPPARGPTGS2
SCHEMBL23387525 0.92 ITGA4 (0.48) ITGA4ITGB1LTA4H
SCHEMBL15105296 0.92 ITGA4 (0.48) ITGA4ITGB1LTA4H
SCHEMBL31070921 0.92 ITGA4 (0.48) ITGA4ITGB1LTA4H
SCHEMBL5719932 0.89 ITGA4 (0.50) ITGA4ITGB1LTA4H
SCHEMBL5719938 0.89 ITGA4 (0.50) ITGA4ITGB1LTA4H
SCHEMBL7709191 0.88 LTA4H (0.49) ITGA4ITGB1LTA4H
SCHEMBL5719732 0.87 ITGA4 (0.48) ITGA4ITGB1LTA4H
Hydrochloric Acid SCHEMBL6510340 0.87 LTA4H (0.46) ITGA4ITGB1LTA4HPPARGPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1144365-B1 INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2004-03-17 EP disclosed
EP-0991619-B1 INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2003-09-10 EP disclosed
US-6596752-B1 Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. TANABE SEIYAKU CO., LTD. (JP) 2003-07-22 US disclosed
US-20030130349-A1 Inhibitors of alpha 4beta1 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2003-07-10 US disclosed
US-6482849-B1 Inhibitors of α4β1 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2002-11-19 US disclosed
US-20020035127-A1 Phenylalanine derivatives CELLTECH THERAPEUTIS, LIMITED 2002-03-21 US disclosed
US-6329372-B1 HETEROCYCLIC AMIDE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. CELLTECH THERAPEUTICS LIMITED (GB) 2001-12-11 US disclosed
US-6197794-B1 ANTIINFLAMAMTORY AGENTS; IMMUNOLOGY DISEASES CELLTECH THERAPEUTICS LIMITED (GB) 2001-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035127-A1 Phenylalanine derivatives PAH, VCAM1, IL4I1 ITGA4 5/4885ITGB1 8/4885LTA4H 112/4885
US-20030130349-A1 Inhibitors of alpha 4beta1 mediated cell adhesion VCAM1, ICAM1, ITGB1 ITGA4 8/4885ITGB1 3/4885LTA4H 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.